Empreses emergents
2015
LEUKOS BIOTECH SLDesenvolupament de nous tractaments i eines de diagnòstic per a la leucèmia. Objectiu terapèutic contra cèl·lules mare leucèmiques en LMA amb atributs que justifiquen la intervenció farmacològica
Adreça
Carrer de Muntaner 383, 08021 Barcelona, Espanya
Dades financeres
Propietat CERCA
Badalona, Spain
2010
Institut de Recerca Contra la Leucèmia Josep Carreras (IJC)
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
Leukos Biotech is a spin-off company from the Josep Carreras Leukaemia Research Institute.
We focus on developing new treatments and diagnostic tools for Leukaemia.
Leukos has generated a proprietary first-in-class, broad chemical space of molecules that are orally available and fulfil the desired target product profile, with strong proof of concept “in vitro”, “ex vivo” and “in vivo” in xenograft and orthotopic models of AML. The first candidate, LK02 for AML and MDS, will be ready for clinical development in 1Q2022. Leukos has validated proprietary mABs for the diagnosis and prognosis of AML patients according to the expression of the target (which has also biomarker attributes)
We focus on developing new treatments and diagnostic tools for Leukaemia.
Leukos has generated a proprietary first-in-class, broad chemical space of molecules that are orally available and fulfil the desired target product profile, with strong proof of concept “in vitro”, “ex vivo” and “in vivo” in xenograft and orthotopic models of AML. The first candidate, LK02 for AML and MDS, will be ready for clinical development in 1Q2022. Leukos has validated proprietary mABs for the diagnosis and prognosis of AML patients according to the expression of the target (which has also biomarker attributes)
Descripció del producte
Since the establishment of the Josep Carreras Leukaemia Research Institute, the Leukemia Stem Cell research group led by Dr. Risueño develops a research program focused on the development of therapeutic strategies for targeting LSCs. An in silico screening was performed to search for already human-approved drugs that may differentially kill LSCs while sparing healthy hematopoietic stem cells (HSCs).
Leukos Biotech holds a license from Josep Carreras Leukaemia Research Institute covering proprietary use of a family of drugs and antibodies with the potencial for diagnosing, prognosing and treating AML patients developed by Dr. Risueño's team at IJC. After 3 years of comprehensive research on the mechanism of action of known serotonin antagonist drugs on AML cells, and recognizing the strong potential of the target in the oncological setting, the company started a medicinal chemistry program aiming to deliver new compounds with high selectivity, high specificity, oral bioavailability and no BBB crossing. As a result, Leukos Biotech has defined a first-in-class broad chemistry space with blockbuster potential. Its first candidate for AML/MDS started IND-enabling work in August 2020 and will be IND-ready by 4Q 2021.
Leukos Biotech holds a license from Josep Carreras Leukaemia Research Institute covering proprietary use of a family of drugs and antibodies with the potencial for diagnosing, prognosing and treating AML patients developed by Dr. Risueño's team at IJC. After 3 years of comprehensive research on the mechanism of action of known serotonin antagonist drugs on AML cells, and recognizing the strong potential of the target in the oncological setting, the company started a medicinal chemistry program aiming to deliver new compounds with high selectivity, high specificity, oral bioavailability and no BBB crossing. As a result, Leukos Biotech has defined a first-in-class broad chemistry space with blockbuster potential. Its first candidate for AML/MDS started IND-enabling work in August 2020 and will be IND-ready by 4Q 2021.